US Food and Drug Administration.Questions and answers on final rule of albuterol MDIs. www.fda.gov/cder/mdi/mdifaqs.htm. Updated may 30, 2008. Accessed October 15, 2008.
2.
Leo HL, Dombkowski KJ, Clark NMThe economic effect of the hydrofluoroalkane albuterol transition on children with asthma. J Allergy Clin Immunol. 2008;121:776-777.
3.
Boyd A.FDA: Patients should switch to HFA inhalers. www.efluxmedia.com/news_FDA_Patients_Should_Switch_to_HFA_Inhalers_18415.html. Published June 2, 2008.
4.
Finegold I.Eliminating CFC-albuterol. www.epocrates.com/company/news/050808.html . Accessed October 15, 2008.
5.
Dolivich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/ American College of Asthma, Allergy, and Immunology. Chest. 2005; 127:335-371.
6.
Leach CLThe CFC to HFA transition and its impact on pulmonary drug development. Respir Care. 2005;50: 1201-1206.
7.
US Environmental Protection Agency.Benefits of the CFC phaseout. http://epa.gov/Ozone/geninfo/benefits.html . Accessed October 15, 2008.
8.
Wysowski DK, Swan J.Use of inhalant medications with and without chlorofluorocarbon propellants in the United States, 1996-2000. J Allergy Clin Immunol. 2002;110:51-53.
9.
Alternative Fluorocarbons Environmental Acceptability Study.Montreal Protocol on Substances that Deplete the Ozone Layer. http://afeas.org/montreal_protocol.html. Updated June 2, 2006. Accessed October 15, 2008.
10.
Brindley A.The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability . J Allergy Clin Immunol. 1999;106:221-226.
11.
Clark A.The physics of aerosol formation by MDIs: limitations of the current approach . J Biopharm Sci. 1992;3:69-76.
12.
Lumry W., Noveck R., Weinstein S., et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann Allergy Asthma Immunol. 2001;86:297-303.
13.
Ramsdell JW , Klinger NM, Ekholm BP, Colice GLSafety of long-term treatment with HFA albuterol . Chest. 1999;115:945-951.
14.
Leach C.Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104: 250-252.
